| Market Cap | 454.99Cr 413.36Cr 381.92Cr 344.98Cr 651.03Cr 43TCr 673.93Cr 4.59TCr 1.82TCr 23TCr 1.71TCr 1.67TCr 73TCr | P/E 2024 |
-51.1x | P/E 2025 | -162x |
|---|---|---|---|---|---|
| Enterprise Value | 469.87Cr 426.88Cr 394.41Cr 356.26Cr 672.32Cr 44TCr 695.97Cr 4.74TCr 1.88TCr 24TCr 1.76TCr 1.73TCr 75TCr | EV / Sales 2024 |
5.69x | EV / Sales 2025 | 7.18x |
| Free-Float |
99.31% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Amicus Therapeutics
| 1 day | +1.57% |
| Manager | Title | Age | Since |
|---|---|---|---|
George Davis
PSD | President | 55 | 27/04/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.57% | +1.65% | - | - | 454.99Cr | ||
| -1.29% | -1.76% | +51.98% | +64.66% | 6.63TCr | ||
| -0.09% | +2.79% | +10.75% | +95.02% | 6.06TCr | ||
| +0.63% | +1.64% | +24.25% | +89.70% | 5.55TCr | ||
| -0.60% | -0.53% | +10.22% | +119.45% | 4.76TCr | ||
| -0.27% | -5.28% | +22.20% | +28.97% | 4.37TCr | ||
| -2.44% | -16.09% | +142.91% | +690.35% | 3.73TCr | ||
| +0.23% | +1.66% | +14.85% | +49.06% | 3.66TCr | ||
| +2.35% | -3.61% | +78.64% | +60.70% | 3.22TCr | ||
| +2.67% | +6.80% | -37.18% | +407.36% | 2.66TCr | ||
| Average | +0.29% | +0.33% | +35.40% | +178.36% | 5TCr | |
| Weighted average by Cap. | -0.04% | +0.33% | +35.23% | +153.27% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 53Cr 48Cr 44Cr 40Cr 76Cr 4.96TCr 78Cr 533.29Cr 211.3Cr 2.66TCr 198.24Cr 194.04Cr 8.43TCr | 63Cr 58Cr 53Cr 48Cr 91Cr 5.95TCr 94Cr 640.21Cr 253.66Cr 3.2TCr 237.98Cr 232.95Cr 10TCr |
| Net income | -5.61Cr -5.1Cr -4.71Cr -4.25Cr -8.03Cr -526.81Cr -8.31Cr -57Cr -22Cr -282.71Cr -21Cr -21Cr -895.5Cr | -2.71Cr -2.46Cr -2.28Cr -2.06Cr -3.88Cr -254.55Cr -4.02Cr -27Cr -11Cr -136.6Cr -10Cr -9.96Cr -432.7Cr |
| Net Debt | 19Cr 18Cr 16Cr 15Cr 28Cr 1.82TCr 29Cr 195.53Cr 77Cr 976.01Cr 73Cr 71Cr 3.09TCr | 15Cr 14Cr 12Cr 11Cr 21Cr 1.4TCr 22Cr 150.23Cr 60Cr 749.91Cr 56Cr 55Cr 2.38TCr |
Employees
-
















